Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NetraMark Holdings ( (TSE:AIAI) ) just unveiled an announcement.
NetraMark Holdings Inc. has appointed Jan Sedway, Ph.D., as Senior Vice President of Clinical Science to bolster its growth and market leadership in AI-driven clinical trials. This strategic move aims to enhance the company’s offerings in psychiatry, oncology, and other therapeutic areas, as it seeks to expand its market share in the rapidly growing global market for AI-driven clinical trial optimization. Dr. Sedway’s extensive experience in clinical research and innovation is expected to accelerate NetraMark’s value delivery to clients and strengthen its industry positioning.
More about NetraMark Holdings
NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions targeted at the pharmaceutical industry. The company offers a unique topology-based algorithm that enables the parsing of patient data into subsets, allowing for the use of various ML methods to transform data into intelligent insights. This technology allows NetraMark to work with smaller datasets and accurately segment diseases and classify patients for drug sensitivity and treatment efficacy.
Average Trading Volume: 55,363
Technical Sentiment Signal: Buy
Current Market Cap: C$105.7M
Learn more about AIAI stock on TipRanks’ Stock Analysis page.